Literature DB >> 25482269

Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.

Matthias Brendel1, Marcus Högenauer1, Andreas Delker1, Julia Sauerbeck1, Peter Bartenstein1, John Seibyl2, Axel Rominger3.   

Abstract

Amyloid positron-emission-tomography (PET) offers an important research and diagnostic tool for investigating Alzheimer's disease (AD). The majority of amyloid PET studies have used the cerebellum as a reference region, and clinical studies have not accounted for atrophy-based partial volume effects (PVE). Longitudinal studies using cerebellum as reference tissue have revealed only small mean increases and high inter-subject variability in amyloid binding. We aimed to test the effects of different reference regions and PVE-correction (PVEC) on the discriminatory power and longitudinal performance of amyloid PET. We analyzed [(18)F]-AV45 PET and T1-weighted MRI data of 962 subjects at baseline and two-year follow-up data of 258 subjects. Cortical composite volume-of-interest (VOI) values (COMP) for tracer uptake were generated using either full brain atlas VOIs, gray matter segmented VOIs or gray matter segmented VOIs after VOI-based PVEC. Standard-uptake-value ratios (SUVR) were calculated by scaling the COMP values to uptake in cerebellum (SUVRCBL), brainstem (SUVRBST) or white matter (SUVRWM). Mean SUV, SUVR, and changes after PVEC were compared at baseline between diagnostic groups of healthy controls (HC; N=316), mild cognitive impairment (MCI; N=483) and AD (N=163). Receiver operating characteristics (ROC) were calculated for the discriminations between HC, MCI and AD, and expressed as area under the curve (AUC). Finally, the longitudinal [(18)F]-AV45-PET data were used to analyze the impact of quantitation procedures on apparent changes in amyloid load over time. Reference region SUV was most constant between diagnosis groups for the white matter. PVEC led to decreases of COMP-SUV in HC (-18%) and MCI (-10%), but increases in AD (+7%). Highest AUCs were found when using PVEC with white matter scaling for the contrast between HC/AD (0.907) or with brainstem scaling for the contrast between HC/MCI (0.658). Longitudinal increases were greatest in all diagnosis groups with application of PVEC, and inter-subject variability was lowest for the white matter reference. Thus, discriminatory power of [(18)F]-AV45-PET was improved by use of a VOI-based PVEC and white matter or brainstem rather than cerebellum reference region. Detection of longitudinal amyloid increases was optimized with PVEC and white matter reference tissue.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F-AV45-PET; Alzheimer's disease; Partial volume effect correction; Reference region

Mesh:

Substances:

Year:  2014        PMID: 25482269     DOI: 10.1016/j.neuroimage.2014.11.055

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  65 in total

1.  Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE.

Authors:  Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Nirubol Tosakulwong; Stephen D Weigand; Bradley J Kemp; Anthony J Spychalla; Prashanthi Vemuri; Ronald C Petersen; Val J Lowe; Clifford R Jack
Journal:  Neuroimage       Date:  2016-08-27       Impact factor: 6.556

2.  Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.

Authors:  Sepideh Shokouhi; Desmond Campbell; Aaron B Brill; Harry E Gwirtsman
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

3.  Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Authors:  Susan M Landau; Allison Fero; Suzanne L Baker; Robert Koeppe; Mark Mintun; Kewei Chen; Eric M Reiman; William J Jagust
Journal:  J Nucl Med       Date:  2015-03-05       Impact factor: 10.057

4.  A new integrated dual time-point amyloid PET/MRI data analysis method.

Authors:  Diego Cecchin; Henryk Barthel; Davide Poggiali; Annachiara Cagnin; Solveig Tiepolt; Pietro Zucchetta; Paolo Turco; Paolo Gallo; Anna Chiara Frigo; Osama Sabri; Franco Bui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

5.  Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden.

Authors:  Janusch Blautzik; Matthias Brendel; Julia Sauerbeck; Sebastian Kotz; Franziska Scheiwein; Peter Bartenstein; John Seibyl; Axel Rominger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

Review 6.  The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Authors:  William J Jagust; Susan M Landau; Robert A Koeppe; Eric M Reiman; Kewei Chen; Chester A Mathis; Julie C Price; Norman L Foster; Angela Y Wang
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

7.  Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET.

Authors:  Tengfei Guo; Matthias Brendel; Timo Grimmer; Axel Rominger; Igor Yakushev
Journal:  J Nucl Med       Date:  2016-10-06       Impact factor: 10.057

8.  Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Authors:  Dana L Tudorascu; Stewart J Anderson; Davneet S Minhas; Zheming Yu; Diane Comer; Patrick Lao; Sigan Hartley; Charles M Laymon; Beth E Snitz; Brian J Lopresti; Sterling Johnson; Julie C Price; Chester A Mathis; Howard J Aizenstein; William E Klunk; Benjamin L Handen; Brad T Christian; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

9.  Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Authors:  Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2018-11-17       Impact factor: 6.556

Review 10.  18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Xavier Bonfill Cosp; Leon Flicker
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.